Legend Biotech (LEGN) Stock Overview
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for LEGN from our risk checks.
LEGN Community Fair Values
Create NarrativeSee what 32 others think this stock is worth. Follow their fair value or set your own to get alerts.
Legend Biotech Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$34.73 |
| 52 Week High | US$59.62 |
| 52 Week Low | US$27.34 |
| Beta | 0.26 |
| 1 Month Change | -10.49% |
| 3 Month Change | 22.16% |
| 1 Year Change | -39.65% |
| 3 Year Change | -24.71% |
| 5 Year Change | 17.45% |
| Change since IPO | -6.14% |
Recent News & Updates
Legend Biotech: Q2 Record Sales Undermined By Losses, Immature Pipeline - Rating Downgrade
Aug 14Here's Why Legend Biotech (NASDAQ:LEGN) Can Manage Its Debt Despite Losing Money
Aug 04
Recent updates
Legend Biotech: Q2 Record Sales Undermined By Losses, Immature Pipeline - Rating Downgrade
Aug 14Here's Why Legend Biotech (NASDAQ:LEGN) Can Manage Its Debt Despite Losing Money
Aug 04There's Reason For Concern Over Legend Biotech Corporation's (NASDAQ:LEGN) Massive 32% Price Jump
Jun 14
Expanding Facilities In Belgium And New Jersey Will Boost Reach
Expanded manufacturing and outpatient approval are set to increase supply and streamline distribution, potentially boosting net margins and revenue.Legend Biotech's Carvykti Is Taking Off, And It's Still Early (Rating Upgrade)
Mar 11Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4)
Jan 07Some Legend Biotech Corporation (NASDAQ:LEGN) Shareholders Look For Exit As Shares Take 26% Pounding
Jan 02Legend Biotech: The Story Brightens
Dec 05Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 15Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion
Sep 18Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges
Jul 30Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances
May 14Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)
Mar 15Legend Biotech: Solid Traction With Carvykti Rollout
Jan 29Legend Biotech wins approval of Carvykti for multiple myeloma in Japan
Sep 27Legend Biotech stock slides on proposed ADS offering
Jul 25Legend Biotech ends Phase 1 trial for lymphoma candidate
Jul 07Shareholder Returns
| LEGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.4% | -0.4% | 0.5% |
| 1Y | -39.7% | -9.9% | 15.7% |
Return vs Industry: LEGN underperformed the US Biotechs industry which returned -9.9% over the past year.
Return vs Market: LEGN underperformed the US Market which returned 15.7% over the past year.
Price Volatility
| LEGN volatility | |
|---|---|
| LEGN Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LEGN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LEGN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 2,800 | Ying Huang | www.legendbiotech.com |
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China.
Legend Biotech Corporation Fundamentals Summary
| LEGN fundamental statistics | |
|---|---|
| Market cap | US$6.41b |
| Earnings (TTM) | -US$325.33m |
| Revenue (TTM) | US$796.84m |
Is LEGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LEGN income statement (TTM) | |
|---|---|
| Revenue | US$796.84m |
| Cost of Revenue | US$698.91m |
| Gross Profit | US$97.93m |
| Other Expenses | US$423.27m |
| Earnings | -US$325.33m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.76 |
| Gross Margin | 12.29% |
| Net Profit Margin | -40.83% |
| Debt/Equity Ratio | 30.0% |
How did LEGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/01 18:37 |
| End of Day Share Price | 2025/08/29 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Legend Biotech Corporation is covered by 29 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Suranjit Mukherjee | BTIG |